156 related articles for article (PubMed ID: 32029404)
1. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).
Aparicio T; Canouï-Poitrine F; Caillet P; François E; Cudennec T; Carola E; Albrand G; Bouvier AM; Petri C; Couturier B; Phelip JM; Bengrine-Lefevre L; Paillaud E
Dig Liver Dis; 2020 May; 52(5):493-505. PubMed ID: 32029404
[TBL] [Abstract][Full Text] [Related]
2. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
Phelip JM; Tougeron D; Léonard D; Benhaim L; Desolneux G; Dupré A; Michel P; Penna C; Tournigand C; Louvet C; Christou N; Chevallier P; Dohan A; Rousseaux B; Bouché O
Dig Liver Dis; 2019 Oct; 51(10):1357-1363. PubMed ID: 31320305
[TBL] [Abstract][Full Text] [Related]
3. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
Gouverneur A; Rouyer M; Grelaud A; Robinson P; Colombani F; Terrebonne E; Smith D; Fourrier-Réglat A; Noize P
Fundam Clin Pharmacol; 2017 Feb; 31(1):104-109. PubMed ID: 27600062
[TBL] [Abstract][Full Text] [Related]
4. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
Weinberg BA; Marshall JL; Hartley M; Salem ME
Clin Adv Hematol Oncol; 2016 Feb; 14(2):116-28. PubMed ID: 27057810
[TBL] [Abstract][Full Text] [Related]
5. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
6. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.
Aranda E; Aparicio J; Alonso V; Garcia-Albeniz X; Garcia-Alfonso P; Salazar R; Valladares M; Vera R; Vieitez JM; Garcia-Carbonero R
Clin Transl Oncol; 2015 Dec; 17(12):972-81. PubMed ID: 26669312
[TBL] [Abstract][Full Text] [Related]
7. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).
Greillier L; Gauvrit M; Paillaud E; Girard N; Montégut C; Boulahssass R; Wislez M; Pamoukdjian F; Corre R; Cabart M; Caillet P; Belaroussi Y; Frasca M; Noize P; Wang P; Mebarki S; Mathoulin-Pelissier S; Couderc AL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159036
[TBL] [Abstract][Full Text] [Related]
9. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
11. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.
Vogel A; Hofheinz RD; Kubicka S; Arnold D
Cancer Treat Rev; 2017 Sep; 59():54-60. PubMed ID: 28738235
[TBL] [Abstract][Full Text] [Related]
12. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.
Ciliberto D; Staropoli N; Caglioti F; Chiellino S; Ierardi A; Ingargiola R; Botta C; Arbitrio M; Correale P; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 May; 125():69-77. PubMed ID: 29650279
[TBL] [Abstract][Full Text] [Related]
13. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
Maillet M; Dréanic J; Dhooge M; Mir O; Brezault C; Goldwasser F; Chaussade S; Coriat R
Anticancer Drugs; 2014 Nov; 25(10):1215-9. PubMed ID: 24858536
[TBL] [Abstract][Full Text] [Related]
14. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
[TBL] [Abstract][Full Text] [Related]
15. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
Bekaii-Saab T; Kim R; Kim TW; O'Connor JM; Strickler JH; Malka D; Sartore-Bianchi A; Bi F; Yamaguchi K; Yoshino T; Prager GW
Clin Colorectal Cancer; 2019 Mar; 18(1):e117-e129. PubMed ID: 30598357
[TBL] [Abstract][Full Text] [Related]
16. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
[TBL] [Abstract][Full Text] [Related]
17. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
18. First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
André T; Saunders M; Kanehisa A; Gandossi E; Fougeray R; Amellal NC; Falcone A
Future Oncol; 2020 Feb; 16(4):21-29. PubMed ID: 31914811
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Bullement A; Underhill S; Fougeray R; Hatswell AJ
Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
[TBL] [Abstract][Full Text] [Related]
20. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
